Literature DB >> 7917234

Evaluation of various virulence tests with low virulence vaccinia virus in mice.

V Ludvíková1, L Kutinová, V Simonová, M Otavová.   

Abstract

Two vaccinia virus (VV) clones, denoted P20 and P21 were derived from the parental VV strain Praha. The residual virulence of these two viruses in mice was compared. Intracerebral inoculation of 21-day-old mice did not reveal any marked difference between the two viruses. Tests using intracerebral inoculation of 10-day-old mice showed that their LD50 differed by 2 log10 pfu, P20 being the more attenuated. The difference between the two viruses increased further when intranasal and intracerebral inoculations of 3-day-old mice were employed. Their LD50 differed by 4 and 5 log10 pfu, respectively. Thus, these tests proved to be the most sensitive for determining residual virulence of VV in mice and thus the most suitable for differentiating among the low virulence VVs. The antibody tests carried out in the surviving mice suggested that the more attenuated virus was less immunogenic than the more virulent virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917234     DOI: 10.1006/biol.1994.1025

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  3 in total

1.  The amino terminus of the vaccinia virus E3 protein is necessary to inhibit the interferon response.

Authors:  Stacy D White; Bertram L Jacobs
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

2.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

3.  ESR and NMR studies provide evidence that phosphatidyl glycerol specifically interacts with poxvirus membranes.

Authors:  Jean-Claude Debouzy; David Crouzier; Anne-Laure Favier; Julien Perino
Journal:  Virol J       Date:  2010-12-31       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.